×
0 0 0.0480349344978165 0.0480349344978165 0.196506550218341 0.14410480349345 0.104803493449782 0.131004366812227
Stockreport

Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials

AKARI THERAPEUTICS PLC ADR (AKTX)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF The final three Paroxysmal Nocturnal Hemoglobinuria (PNH) patients enrolled into the Phase II COBALT trial with the revised dosing regimen had median LDH of Phase III clinical trial in naive PNH patients anticipated to begin by the end of first quarter 2018Phase II clinical trial of Coversin in atypical Hemolytic Uremic Syndrome (aHUS) initiated Two Phase II clinical trials of Coversin, in Atopic Keratoconjunctivitis (AKC) and in Bullous Pemphigoid (BP), anticipated to begin in first half 2018 NEW YORK and LONDON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announces additional data for its Phase II COBALT clinical trial and provides an update on other clinical trials with Coversin. The final three patients enrolled in the eight patient 90-day open-label Phase II s [Read more]

IMPACT SNAPSHOT EVENT TIME: AKTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS